Q3 2024 Vanda Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Vanda Pharmaceuticals Inc (VNDA) reported a 23% increase in total revenues for Q3 2024 compared to Q3 2023, driven by the introduction of Ponvory revenue and increased Fanapt revenue.
- The company completed the first phase of its sales force expansion, increasing to 150 representatives, with plans to reach 200 by year-end, supporting the launch of Fanapt in bipolar one disorder.
- Early indicators of commercial progress for Fanapt are encouraging, with a 90% increase in new patient starts compared to Q3 2023.
- Vanda Pharmaceuticals Inc (VNDA) has initiated a second phase of sales force expansion, indicating confidence in continued growth and market adoption.
- The company is actively pursuing new drug applications and clinical trials for expanded indications, such as Miltefosine for schizophrenia and bipolar disorder, and Ponvory for psoriasis and ulcerative colitis.
- Total revenues for the first nine months of 2024 decreased by 1% compared to the same period in 2023, primarily due to decreased Hetlioz revenue from generic competition.
- Vanda Pharmaceuticals Inc (VNDA) recorded a net loss of $14 million for the first nine months of 2024, compared to a net income of $4.9 million for the same period in 2023.
- Operating expenses increased by $21.7 million for the first nine months of 2024 compared to the same period in 2023, driven by higher SG&A expenses and legal activities.
- The FDA denied approval for Tradipitant for gastroparesis, which was a setback for the company, as they believed the application demonstrated substantial evidence of efficacy.
- Ponvory net product sales decreased by 32% in Q3 2024 compared to Q2 2024, attributed to inventory destocking during the transition of distribution responsibilities.
Hello and thank you for standing by. At this time. I would like to welcome you to the Q3 2024 Vanda Pharmaceuticals Inc., earnings conference call. (Operator Instructions)
I would now like to turn the conference over to Kevin Moran, Vanda's Chief Financial Officer. Please go ahead, sir.
Thank you, Jericho. Good afternoon and thank you for joining us to discuss Vanda pharmaceuticals' third quarter, 2024 performance, our third quarter, 2024 results were released this afternoon and are available on the S ECs Edgar system and on our website www dot vandapharma dotcom.
In addition, we are providing live and archived versions of this conference call on our website.
Joining me on today's call is Dr Mihales Polymeropoulos, our President, Chief Executive Officer and Chairman of the board and Tim Williams, our general counsel following my introductory remarks, Mahal will update you on our ongoing activities. I will then comment on our financial
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
